Work

Toward a better understanding of inflammatory microvesicles in alcohol use disorder

Year: 2021

Type: article

Abstract: The Department of Veterans Affairs (VA) and Oregon Health & Science University (OHSU) own recombinant T-cell receptor ligand technology, an immunotherapy under investigation for the treatment of substance use disorders and other inflammatory conditions. The VA, OHSU, and Dr. Loftis have rights to royalties from the licensing agreement with Artielle Immunotherapeutics. This potential conflict of interest has been reviewed and is managed by the Conflict of Interest Committees at the VA Portland Health Care System and OHSU. Dr. Sandau reports no conflict of interest. The peer review history for this article is available at https://publons.com/publon/10.1002/jnr.24930. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Source: Journal of Neuroscience Research

DOI: 10.1002/jnr.24930

Authors: Ursula S. Sandau, Jennifer M. Loftis

Institutions: Oregon Health & Science University, Portland VA Medical Center, VA Portland Health Care System

Language: English

Topic: Substance Abuse Treatment and Outcomes

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Veterans Affairs, National Institute on Drug Abuse